Clinical Trial Update: Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia [Phase 3]

View source ↗

Summary

Phase 3 trial of sarizotan in Parkinson's disease patients with treatment-related dyskinesia completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Parkinson Disease

Drugs mentioned

• Sarizotan (sarizotan)

Snippet

Sponsor: EMD Serono | Conditions: Parkinson's Disease, Dyskinesia | Phase 3 | Status: COMPLETED | Results posted: 2018-04-02